Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- AstraZeneca Plc (NASDAQ:AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
- Under the deal, VaxEquity could receive up to $195 million in milestones payments, in addition to royalties on approved drugs.
- VaxEquity was founded in 2020 by Imperial vaccinologist Robin Shattock and Morningside Group.
- "This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox," said Mene Pangalos, EVP, BioPharmaceuticals R&D at AstraZeneca.
- AstraZeneca, under the deal, has the option to collaborate on 26 drug targets and invest in VaxEquity to further the development of the saRNA platform.
- "We believe self-amplifying RNA, once optimized, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest," Pangalos added.
- Price Action: AZN stock is up 1.28% at $59.49 during the premarket session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!